Compare iShares Core MSCI EAFE ETF (IEFA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Sana Biotechnology Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $101.02, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| IEFA | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $101.09 | $5.92 |
52-Week Low | $84.72 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $101.02, up 0.49% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on developed international equities outside the U.S. and Canada, offering diversification and a dividend yield of 3.30% (The Motley Fool, 2026-06-17). Recent news highlights its cost efficiency and income appeal compared to peers like EFA and VXUS.
The outlook remains positive due to international diversification benefits and potential Fed rate cuts, but risks include currency fluctuations and geopolitical tensions. Analyst sentiment is favorable, emphasizing lower expense ratios and stable dividend income for long-term investors.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
